ASCENDIS PHARMA
Ascendis Pharma A/S
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87247108 |
| Registration Number | 5259688 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Domestic Representative | Lawrence E. Abelman |
| Attorney Name | Lawrence E. Abelman |
| Attorney Docket Number | 878489 |
| Law Office Assigned | L30 |
| Employee Name | BORSUK, ESTHER A |
Timeline
| 2009-12-00 | Date of First Use |
| 2016-11-23 | Application Filed |
| 2017-04-25 | Published for Opposition |
| 2017-08-08 | Location: PUBLICATION AND ISSUE SECTION |
| 2017-08-08 | Status: Live/Registered |
| 2017-08-08 | Trademark Registered |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Ascendis Pharma A/S |
| Address | Tuborg Boulevard 5 Hellerup DK DK-2900 |
| Legal Entity Type | Limited Liability Company |
| Legal Entity State | DK |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| D10000 | "PHARMA" |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2016-11-26 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2016-12-01 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2017-03-01 | 3 DOCK D:Assigned to Examiner |
| EXAMINERS AMENDMENT -WRITTEN | 2017-03-07 | 4 CNEA R:Renewal |
| EXAMINERS AMENDMENT E-MAILED | 2017-03-07 | 5 GNEA F:First Action |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2017-03-07 | 6 GNEN O:Outgoing Correspondence |
| EXAMINER'S AMENDMENT ENTERED | 2017-03-07 | 7 XAEC I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2017-03-07 | 8 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2017-04-05 | 9 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2017-04-25 | 10 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2017-04-25 | 11 NPUB E:E-Mail |
| EXTENSION OF TIME TO OPPOSE RECEIVED | 2017-05-24 | 12 ETOF T:TTAB Proceeding |
| EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | 2017-07-05 | 13 ETOP T:TTAB Proceeding |
| REGISTERED-PRINCIPAL REGISTER | 2017-08-08 | 14 R.PR A:Allowance for Publication |
| COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | 2022-08-08 | 15 REM1 E:E-Mail |
| TEAS SECTION 8 RECEIVED | 2023-08-08 | 16 ES8R I:Incoming Correspondence |
| CASE ASSIGNED TO POST REGISTRATION PARALEGAL | 2023-11-21 | 17 APRE A:Allowance for Publication |
| REGISTERED - SEC. 8 (6-YR) ACCEPTED | 2023-11-21 | 18 8.OK O:Outgoing Correspondence |
| NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | 2023-11-21 | 19 NAS8 E:E-Mail |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ASCENDIS PHARMA 87247108 5259688 Live/Registered |
Ascendis Pharma A/S 2016-11-23 |
 ASCENDIS PHARMA 79225147 not registered Live/Pending |
Ascendis Pharma A/S 2017-10-11 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 